Ann: Q3 Investor Call Advance Notice, page-11

can’t control how the market reacts/values these milestones

but with first dose of VP-001 it’s more likely to reach market than not (grading us based on data set + team, we should be on HD+ grade, market currently valuing us below a pass mark)

the scientific team is lead by Sue F, and with Sri on board - if PYC-001 and PYC-002 milestones are completed timely then the market will be more aware.

I believe the market isn’t aware/have assigned any value to our CNS efforts, at the end of Q3 they will hopefully be very aware via the Q3 call, or earlier via milestone announcement.